<

CARDIOL THERAPEUTICS Original-Research: Cardiol Therapeutics (von GBC AG): Buy

Transparency directive : regulatory news

13/08/2021 11:31

Original-Research: Cardiol Therapeutics - von GBC AG

Einstufung von GBC AG zu Cardiol Therapeutics

Unternehmen: Cardiol Therapeutics
ISIN: CA14161Y2006

Anlass der Studie: Research Comment
Empfehlung: Buy
Kursziel: 17.49 CAD
Kursziel auf Sicht von: 31.12.2022
Letzte Ratingänderung:
Analyst: Julien Desrosiers; Felix Haugg

Cardiol Therapeutics successful NASDAQ listing

NASDAQ Capital Market LLC has granted Cardiol final approval to list its common shares on NASDAQ. On August 10, 2021, the Company's shares started trading under the ticker 'CRDL'.

David Elsley, President & CEO of Cardiol Therapeutics, said, 'Listing on NASDAQ is a major milestone for our Company as NASDAQ is the premier global stock exchange for life science and biotechnology companies. As we continue to advance the research and clinical development of novel therapeutic strategies for inflammatory heart disease, we believe the Nasdaq listing will enable the execution of a more effective investor relations program aimed at increasing awareness of the Cardiol story amongst investors and analysts in the U.S. and ultimately lead to increased shareholder value.'

This listing allows the company to access the world's largest biotechnology stock trading and fundraising center. This should help the company access more U.S. based retail and institutional investors. We believe this will continue raise awareness about the company and their developing story.

Due to the roll-over effect resulting from the extension of the price target to 31.12.2022 (previously: 31.12.2021), our price target increases to 17.49 CAD (previously: 15.77 CAD). We continue to assign the BUY rating.

Die vollständige Analyse können Sie hier downloaden: http://www.more-ir.de/d/22769.pdf

Kontakt für Rückfragen
GBC AG
Halderstraße 27
86150 Augsburg
0821 / 241133 0
research@gbc-ag.de
+++++++++++++++
Offenlegung möglicher Interessenskonflikte nach § 85 WpHG und Art. 20 MAR. Beim oben analysierten Unternehmen ist folgender möglicher Interessenkonflikt gegeben: (5a,6a,7,11); Einen Katalog möglicher Interessenkonflikte finden Sie unter: http://www.gbc-ag.de/de/Offenlegung
+++++++++++++++
Date and time of completion of this research: 13/08/2021 (09:15 am) Date and time of first distribution: 13/08/2021 (11:30 am)

-------------------übermittelt durch die EQS Group AG.-------------------

Für den Inhalt der Mitteilung bzw. Research ist alleine der Herausgeber bzw. Ersteller der Studie verantwortlich. Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.



Other stories

28/03/2024 18:00
28/03/2024 12:25
28/03/2024 16:55
28/03/2024 17:37
28/03/2024 13:03
28/03/2024 20:53
28/03/2024 20:53
28/03/2024 14:31
28/03/2024 20:14
28/03/2024 16:37
28/03/2024 20:23
28/03/2024 14:54
28/03/2024 18:38
28/03/2024 16:34
28/03/2024 19:49
28/03/2024 20:51
28/03/2024 09:59
28/03/2024 08:12
27/03/2024 15:52
28/03/2024 14:28
28/03/2024 13:31
27/03/2024 17:41
28/03/2024 21:31
28/03/2024 19:00
28/03/2024 13:11
28/03/2024 13:49
28/03/2024 19:55
28/03/2024 15:27
28/03/2024 13:29
28/03/2024 17:34
27/03/2024 21:46
28/03/2024 17:55
27/03/2024 13:40
28/03/2024 17:23
28/03/2024 13:25
28/03/2024 12:57
28/03/2024 16:44
28/03/2024 02:42